Global Rx Spending To Hit $1.4tn In 2020, IMS Institute Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While two-thirds of pharmaceutical use by volume will be in "pharmerging markets," developed markets will continue to account for the majority of spending due to use of higher-priced brands, IMS Institute for Healthcare Informatics projects. Overall growth will be at slightly lower pace than seen in last five years.
You may also be interested in...
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
Are Manufacturers Willing To Do Outcomes-Based Pricing? Payers Are Skeptical
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.